NCT05360680 2026-01-22A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersCue BiopharmaPhase 1 Completed42 enrolled
NCT02085148 2024-04-22A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard TherapyBayerPhase 1 Completed62 enrolled
NCT02498665 2023-11-14A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced MalignanciesSumitomo Pharma America, Inc.Phase 1 Completed24 enrolled
NCT02982941 2022-02-08Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsMacroGenicsPhase 1 Completed25 enrolled
NCT01222780 2020-01-18To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory CancerAcrotech Biopharma Inc.Phase 1 Completed22 enrolled
NCT01621542 2019-07-17Clinical Study of WT2725 in Patients With Advanced MalignanciesSumitomo Pharma America, Inc.Phase 1 Completed64 enrolled 16 charts
NCT01169584 2016-01-21Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsSillaJen, Inc.Phase 1 Completed6 enrolled
NCT01598454 2015-07-29Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated GangliosidesLaboratorio Elea Phoenix S.A.Phase 1 Completed15 enrolled
NCT00314925 2010-02-25Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine FeaturesNeotropixPhase 1 Unknown60 enrolled